Recursion provided Roche and Genentech with a whole‑genome microglia phenomap derived from a massive imaging perturbation set; Roche triggered a $30 million milestone payment that lifted total cash from the partnership to $213 million so far. The map covers 46 million microglial images and is positioned to reveal novel neurodegenerative targets. The partnership has already optioned multiple phenomaps, and Roche plans to use Recursion’s OS across dozens of discovery programs. The microglia dataset complements prior neural phenomaps and underscores pharma demand for AI‑driven phenotypic screening at unprecedented scale. The milestone demonstrates tangible cash value for computational biology platforms and will accelerate target validation and preclinical work in Alzheimer’s, Parkinson’s and other CNS diseases.